Skip to main content
Signal8

Flyte Aviation, Inc. (VTAK) Form 8-K — Nov 16, 2026

$VTAKForm 8-KItems 2.02, 9.01Filed Nov 16, 2026, 5:29 PM ET0001437749-26-037257Original filing

Flyte Aviation reported record Q3 2026 revenue of $1.838 million, up 145% sequentially, with flight hours up 129% and more than 99% of flights fulfilled on its own fleet. Aviation is now the sole continuing operation following the classification of the legacy MedTech segment as discontinued operations. The company reported a net loss of $15.1 million, including a $13.3 million non-cash impairment on MedTech assets held for sale, with a $1.9 million loss from continuing operations and just $2.4 million in cash remaining at quarter end. On November 1, Flyte signed a non-binding LOI to sell Catheter Precision's VIVO and LockeT assets by year-end 2026.

Key figures

Revenue
1838000
Cash Position
2400000
Medtech revenue
280000
Impairment charge
13300000
Jets coming online q4
3
Medtech revenue yoy growth pct
24
Time flown per leg avg minutes
52
Loss from continuing operations
1900000
Flight hours sequential growth pct
129
Medtech revenue sequential growth pct
4
Aviation revenue sequential growth pct
145

AI analysis

Red flags4 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.